Amarin Corp. ADR Stock
Amarin Corp. ADR Stock
With 6 Sell predictions and no Buy predictions the community is very low on the Amarin Corp. ADR stock.
On the other hand, the target price of 8 € is above the current price of 0.41 € for Amarin Corp. ADR, so the potential is actually 1860.78%.
So far the community has only identified positive things for Amarin Corp. ADR stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Amarin Corporation plc (Symbol AMRN) is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to improve cardiovascular health. The company's main product, Vascepa, is a prescription medication that has been approved by the US FDA for use as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia. Vascepa has also shown to reduce the risk of cardiovascular events such as heart attack and stroke in patients with elevated cardiovascular risk. As a listed company, Amarin is publicly traded on the NASDAQ stock exchange and has a market capitalization of approximately $5 billion as of August 2021.
Pros and Cons of Amarin Corp. ADR in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
M***** P*******
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Amarin Corp. ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Amarin Corp. ADR | - | - | - | - | - | - | - |
| Genus plc | -0.680% | 4.255% | 4.255% | 45.545% | 64.246% | -13.018% | -34.404% |
| Novocure Ltd | -1.190% | -8.174% | -3.254% | -63.646% | -65.282% | -86.701% | -91.689% |
| Ironwood Pharmaceuticals | 0.640% | -5.455% | 95.000% | -6.587% | -25.714% | -73.099% | -68.163% |
Comments
Amarin Corporation PLC (NASDAQ: AMRN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $7.00 to $12.00. They now have a "sell" rating on the stock.
Show more
Ratings data for AMRN provided by MarketBeat
Amarin Co. plc (NASDAQ: AMRN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $20.00 to $7.00. They now have a "sell" rating on the stock.
Show more
Ratings data for AMRN provided by MarketBeat
Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for AMRN provided by MarketBeat